B.More, a non-profit lifescience company, is backing clinical research for regulatory approval of psychedelic medicines to treat Alcohol Use Disorder (AUD) and other addictions. Our research, along with Usona and clinical trials at NYU, aims to support the FDA approval of psilocybin as a prescription medication. Together, we can bring psilocybin to the market to empower those who currently don’t have any other assuring options. Psychedelic medicines show promise to treat substance abuse, addictions, and alcoholism, as demonstrated through clinical studies. B.More’s foundation is established upon collaborations with leading institutions, renowned key researchers in AAUD and addiction, a leadership team, and scientific advisors steeped in experience to deliver value in breakthrough treatments for alcoholism and other addictions. Since 2010, Founder Carey Turnbull has worked in commercial early-stage drug development for half a dozen companies variously as an investor, founder, and CEO. He is on the advisory board of the NYU School of Medicine Department of Psychiatry Psychedelic Research Group, for the Psilocybin Alcohol Use Disorder study, and has assisted in the founding of Yale University’s extensive psilocybin research program. Mr. Turnbull is a member of the board of two Foundations: Heffter Research Institute and Usona Institute, both of which promote research on psychedelic plants and drugs at leading University research departments.